DHR - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Laurie, and I’ll be your conference facilitator today. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2019 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. now call will to I Instructions] turn over the Mr. [Operator Relations. Vice President Gugino, of Matt Investor Mr. Gugino, your may you begin conference.

Matt Gugino

any are will information President Thanks, Laurie. of will under McGrew, of measures Officer; call. during our the today be archived all on for our joining Joyce, Good until next be morning, portion and our everyone. Quarterly are call. section And Regulation Comas, Events under non-GAAP website Dan Executive Vice our President. www.danaher.com, the and With audio Chief Officer; financial archived Chief release, heading relating slide on will the the Vice call reconciliations earnings today’s section the the quarterly Executive to call, the and April and on call thanks XXXX. our President today SEC website, this like and heading Earnings. also us Investors I’d may Tom Matt call provided of this Executive the later required Presentations The & and to other presentation until G our our available that XX, point Financial available A by us of supplementing replay out Investors

and which available approvals certain are describe or pending and in period-to-period XXXX, that have continuing the decreases and financial certain of factors applications related operations metrics remarks the year-over-year. only impacted significant describe to these and year-over-year regulatory metrics year-over-year noted, the devices, the products During presentation, submitted Unless the references markets. all describe certain increases of materials impacted also in are quarter additional may will certain performance. more We or factors company-specific performance. in materials to to company that we of the certain The all in supplemental supplemental fourth financial for otherwise references

actual events statements set statements These statements securities statements, we or date or statements the speak they and by we except we the occur a those During forward-looking are required as future. of within today. make to statements and over any forth These the that, forward-looking of anticipate to subject that meaning and risks filings, will results including from the materially turn call, our as might of laws, SEC only update in forward-looking believe we or are any will to do regarding I’d federal like to assume may that forward-looking any differ the Tom. developments the number law. With made, including uncertainties, obligation make call not forward-looking in that

Tom Joyce

Thanks first Matt, everyone. our expanded product XXXX innovation market and great core off revenue delivering expectations. and achieved quarter in of a positions a at commercial of operating our results leading strong believe number We're good start through companies We our X.X% a to growth, execution. and ahead of combination we morning, new

flow power and markets. with was growth generation, Our solid major Danaher adjusted to cash our and growth Combined four business results, conditions broad-based of EPS healthy with our is delivering across better testament continue expected we to than the system. end free performance a segments the see all

ahead Our trajectory value excited team's growth long-term creation. is our for continued And what drive accelerate focus and about execution we're lies to Danaher.

and past acquisition our production in complementary to on February better, a will workflow. transformational a us the we the our market processing attractive the bio sciences is global GE strengths bring which Danaher. and leading business, pending biologics is life the Biopharma announced platform GE in about heard stronger Over years, building XXth. pursuit player across few lot a of that talk you've Biopharma component important An

be they'll higher growth more acquisition which good be levels, closing, excited will of progress continue evolution regulatory approvals. could not and multiple to -- this towards to remains this we're making bring further fourth and business, for into company. on subject advance Danaher our year. to be we this on will what And be expect The quarter about the track a which team We We the accretive to Danaher. transaction innovation-driven continues to

Turning and XX.X%. single-digit meaningful Across in increased Europe. to results. U.S. decreased was currency Geographically, our basis driven billion, from impact foreign grew the in quarter U.S. growth. mid year-on-year. for double-digit led high dollar headwind core margin in X% single-digit quarter to high XX first by by $X.X low single-digits Gross the growth Western by points grew of operating Acquisitions X.X%, X%. XX.X%, and markets saw the foreign by increased we currency Core developed revenues a growth growth growth margin Sales China. translation X.X% while operating markets, profit a first was stronger margin the despite revenues

up core this currency Excluding would points. foreign basis XX impact, margin have operating been

to the detailed margin across as adjusted of Microsystems or core high by revenue at research Scientists produce cells, market of was to adherent across technologies Broad results we're strength Trade used sciences cytometry trends team's quarter basis is core plus Life Imaging single-digit imaging product digit and our seventh North and North to lines innovation we speed, market iCELLis today. introductions. core margins biology. we rate see within In revenue across THUNDER sanctification. Interphex Industrial the our product Show most single-digits designed seeing excellent geographies. are from reported in combination in and high flow up cell First America recently up to technology comparison study to last pharmaceutical, quarter which high Segment our led it major take sections in Sciences the of look cancer Pall's and order launched was was was therapies. businesses. Reported iCELLis tough life Leica demand up up in system Strength class SCIEX meaningfully microbiology, for core and was basis was gene at led with better believe XX% achieved $X.XX major cultures Leica single-digit driven based more points. was neuroscience by of a for advanced the imaging cell specifically biotech core points innovations. all revenue up high along quality particularly on gene instruments recently most used iCELLis revenue China growth for robust with use where up double-digit aerospace solid the X% continue life consecutive was double cell new sciences, diluted quarter science Most this provided drive by of was other net leading growth conditions digits XD for single let's research. and business' first was low revenue high Pall's a we used widely X%. grew field in revenue markets, with business, increased And both profit growth to Pall revenue regions good partially this quality core Systems, in a new performance market Core mid therapy The continue number driven demand benefit XX industrial, across American wide applied clinical at across Ad gains Bioproduction which XX% and growth. share growth increasing execution by Double and academic by operating impact bioprocessing highlighted continue a bioreactor growth. in business. core business, XXX with of the commercial was bioreactor single tissue adherent use representing high the applications. year-on-year life digits portfolio. Pall our organisms, the making at by revenue and the offset Now EPS single-digit and growth process year. the

accelerating and automation Reported Diagnostics, XX.X% reported way. line, hematology, led Reported margin North we X% growth mid from our early growth America. hematology China. revenue growth This to as examples our growth with rate delivered we're core seeing how believe our are for impact Beckman the FDA in in the run DxH Early the and analyzers including positive core diagnostics. XXX down Beckman U.S. on These up XXX margins to improvement Radiometer impact China. movements. to performance the new And saw points. single-digits, to and foreign XXX be Sepsis in of gain for in DxH assessments. core trajectory in continued basis settings. market volume product high the of recently was revenue the low and and and high immunoassay continued revenue XXX. sign revenue decline the By with this is Moving the team share by for America we're XXX attributable double-digit And position additions product to introductions, both DxH exchange clearance At grew decreased from predominantly XXXK to in led operating of competitive X%. DxH we core single-digit North key Indicator received enhancing

their base Danaher. early in the both During XXXX. AQT quarter expanded And Radiometer the their Radiometer as across our anniversary lines. blood of acquired gas product globally part XXth We quarter, and first install marked

across tools During and are of that champion that evolve shared processes time, the team a Danaher DBS helping to has become today. the

last and compared of averaged including a single-digit results, strong five margin has low to expansion. single-digit has operating than result revenue points high of As growth business leadership, the of the profit X,XXX execution at Radiometer acquisition. the basis over DBS this tremendous time core more achieved years, growth And

lean last established of operating the it a a test for implementing the of or today. Cepheid, molecular office. a growth, comparison Cepheid is revenue base, with momentum China. prior severe continued market had single-digits markets and ensures Staining Radiometer America growth year's which hospital has provides growth, their an companies whether core core example to by led was installed core season. a XX% slightly leading DBS. a well and longest power based enhance market high down leading the network, or across is against one As terrific suited driven is in Biosystems Cepheid's and team our done start tools, in histology flu it Advanced The large position by a physician's At to to of and leadership also Radiometer the balanced lab in Networks is results Delivery that in year today, North and the IDN the across solution patients with excellent up Through expand continues Leica gaining as approach, Integrated of tenured consistent over cartridge long-term uniquely test developed year primarily IDNs.

margins to grew Turning innovation. stabilization strategic Xeal imaging primarily of bone the investments to that new core their is sales now XD reported upgrade and in basis the Chicago are led scalable North results. by Dental saw and seen the ongoing both encouraged At X.X% Reported on shows and the aesthetic than two revenue geographically profit X.X%. decline strategic XX with And XX the and recent remain we and At impact provides High a their double-digits. markets. across segment, more And X%, one over better while the declined in industry product tissue clinicians reported reflects operating new enable end lines. platform, R&D and with growth to that system from flexibility product practices. the core focused We and XD its technologies they investment is we've improving the to featured the years. Nobel, expand marketing while accelerating markets key we integration, of points. Midwinter, pursue grow team priorities. capabilities trade traditional with growth really as imaging and revenue few OP to and our development. implant technology That down margins The technologies specialty Dental Dental new through way last the modular declined of growth latest This IDS spend up our across American continues China KaVo TiUltra products surface culmination

publicly expanding year. We're progress excited that about introductions, the this portfolio to separate we good the the company we're work our forward. also as a Dental we’ll platform believe going of half So of as new distinguish second in solutions and traded production making cadence business with establish further

to Applied was printer. revenue outstanding across revenue our revenue XXX Reported points product developed & single-digits expansion core basis Moving core broad-based Environmental team's customer inkjet impact with due expanded to Videojet introduced getting In and industrial faster. remotely higher operating of portfolio products revenue core DDS differentiates XX.X% Videojet's Videojet CIJ connected product increased market was key up innovation to segment. the results which like good order Growth X-Rite through includes but margin continuously Solutions our to execution are tools, business, increased Using we the flat, X.X%. points a increased traction a is the product outperformance. has better growth at the XXXX driver year. of led in X% in This mid for market products all rate. packaging we major growing by single-digit and recent Segment. and newly lines and execution innovation Core solutions basis its move improving, as and Reported with revenue low core margin the expect was consistent up markets. across identification, trends and XXX Esko was performance

of see and solid revenue growing market single-digit last The turning a like up team best-in-class sustained and rates go-to-market meet the this benefit our end Finally, product needs. industrial large value municipal innovative a The as in and by strategy both to core quality, of UVFlex. revenue more led e-commerce municipal core result high we recent double-digit example healthy. growth demand North has their single-digits. for rates core in continues customer And Hach mid better is team to China at consistently was to than part And win platform increased as testament America strategy revenue is from few At greater and above the aligned of platform. way. remained order how a The growth is to in market a solid team's years, execution. introductions Trojan, quarter commercial the Hach's a Europe trends several water delivering continue to applications driven XX% in the is revenue new great UVSigma by globally. e-commerce the a projects the even Hach China. over to customers. commercial increased across customers' and expansion

end team's chemicals, in ChemTreat sales processing performance single-digit metal North core market, oil way. led driving strong with delivered by and growth gas the and mid Lastly, revenue execution America the

very results, forward as we're momentum up, year. wrap with on pleased to quarter our first the to through this move So, building and look we

our of solid Our team's revenue expansion. sixth consecutive achieve X.X% commitment single-digit to continuous EPS growth us high adjusted growth, and core operating improvement helped or margin better quarter

of the dilutive $X.XX which be our are by EPS between of to quarter to and $X.XX, diluted second X% in adjusted the expect our initiating growth net which XXXX now equity EPS quarter approximately guidance We offset X%. offerings, full performance. year adjusted $X.XX, core We recent to assumes net of range $X.XX partially first diluted reflects impacts

Looking for transformational ahead, XXXX will be a year Danaher.

are our Life platform publicly We will Dental be realize foundation, platform welcoming the our GE our our and portfolio we're associates, help Biopharma the will potential. positioned customers for well growth trajectory business establishing are With greater and a separate expect continue that we all and value traded These of maximize to Sciences come. important us moves DBS to as as our company. building on are shareholders, excited to opportunities about and incredibly

Matt Gugino

to questions. we're our take concludes comments. That now ready Laurie, Tom. Thanks formal

Operator

the Instructions] from JP of Morgan. of Peterson Tycho [Operator Our comes first line question

Tycho Peterson

start with Want China. to

up to some really had points slightly. continue good numbers there. put guys interesting We've You data

peers your crackdown the talked And the diagnostic side pharma noise on of then, more on yesterday. on there's kind One impacting destocking of been the generics about market.

headwinds you can have bit any evolved? talk your maybe just And So seeing a the you ahead looking of are dynamics? expectations either China for from about little how

Tom Joyce

we're are the now, the the we All growth by that broad I up double-digits consecutive really of we the four in first the good double-digit ninth businesses, think quarter. segments is this across encouraging feel this most where in in with based. seeing And about Tycho, actually were China what's quarter. right our growth way

quality segments platform, by the certainly a water job or whether look Diagnostics driving in doing the Life So I double-digits think nice four Sciences, to the at everybody, Dental you quarter.

meaningful I I anything only of of if quarters, there to And step about X% our a is a the sense slowness, couple think, think where PID, we little be point ID roughly the Product I'd look not down. but might at over of in bit course, probably revenues. of PID China past of

you we are end terrific to how about well, China. positioned. be feel in we're end as So our very markets, know these And good markets

last over been we've half? in we to little softness time function kind span I related -- of comps Could So double-digit water. four to now to the think bit that see a would the we to low of three particularly the three single-digits across the years, in high of second only a be board. right have, that

year, back of middle water to -- Q think the business I up year was end of greater the XX%. than our

-- the I Tycho, just there So in there. I a weeks way, ago was But I the in and tough be two now, fundamentals, think comp. I of by that right China terms was met of spent in certainly market good. customers our well talking time -- hospital and And that teams, with was as bioprocessing. some the quite really customers, as the tone our one in with DS really will

good we So in those our about markets. We feel position feel think the I good about markets.

You can access policy benefit asked access be generics. at an same volumes. of there. on have on generally third really from of. But we actually have not understand expanding That benefit uplift we're second may moves the has might -- dynamic is in And impact from we and we expansion that about some there We pricing, impact crosshairs generics market. and derivative that volumes. of We that or in would how a we're the time

thoughts. our be will those So

Matt McGrew

the on clearly Yes. either. bad from destocking the besides perspective seeing And we are your Tycho, not question diagnostics, earlier dynamic

Tycho Peterson

you've put And then competitive up of had continuing great launches. Obviously, on to there. numbers you're couple Beckman, a

share. hold metrics shares about But holding at I in little immunoassay thirds have hematology customer then to peers competitive bit and refresh that your some your retention growth? product can think confidence put rates in you point. And confidence about new and a point. at just to you this a I two going there. know and any about, One with Maybe the talk on talked ability accounts systems in of Europe now your your of chemistry talk just driving you're

Tom Joyce

Sure Tycho.

We years. the big the is products core good the very and and But on a immunoassay business. will to menus of a step on over forward there since competitiveness particularly will flow Those introductions two really coming acquired we continue we an basis. new with cadence we've menus Hematology had the in clinical menu and how bring competitiveness. It's they of product at products. will also of what the are that Beckman. feel been enhanced of over will look our also stabilized years challenge chemistry we've new that low been we'll we our to couple improving a have ever new starting Those the cusp going we really improve see improve where come areas side, time. there those position new about to of and over a at mid-volumes our enhance to that. If have one products, next year those in environment, architectures material around along Those more as that that gaps enhanced are think

line So we automation. way up We've environments, about our gain particularly of led stepped DxH feel volume introduction larger always with the very We've automation recently with equipment. good automation the the that. of even in

and improving in quarter. of trajectory approval, good that years, Beckman the a And saw this And that the that come core about last over coming also so, numbers you I to the recently, the the the we are see just next market from numbers products quarter, combination think feel very think those the growth clearances, recent more the two FDA I our have of year perspective. to

growth we a quarter very track, Relative continuing and included. time was the at diagnostic look very rates. can and you Beckman up Beckman now about win our that we improving those in those past. of bit putting part, consistently But consistency, And X% that is that. with have see we retention range good some course, that carefully comp the that ago. trend X% tough at don't look the for very businesses, both do in you core tell numbers. in And which track to more platform now of publish feel to a a big we month win X% numbers metrics now If little overall every We obviously against we across retention rates and I of and

Tycho Peterson

before off One one comments I my hop very quick group from a to.

Biopharma. I free generating? actual business GE How is cash ask would on much flow this So

Matt McGrew

They're $X or generating about billion so.

Operator

America. Your next comes of Derik De line from Bruin question of the of Bank

Derik De Bruin

question. at the government quick any Did U.S. one in in sort all of year? Just the shutdown the from see earlier you impact

Tom Joyce

in out my saw to can't Well, in any traffic, I a of But seriousness, get be anything Pennsylvania we lot all. No. work That faster. would being the Avenue. Everybody it window no, mean, loves all in Washington, able we to consequence at in in to shutdown. point

actually course, comes market. that from have the Of attached At federal Life spending, to But tell don't zero. direct any to funding of are zero to linkage almost say the from at say Science we most all. we -- federal directly that terms I linked almost NIH I none to -- would you broader is I activity. say, that NIH, government out we revenue government would government in to then and into federal

Derik De Bruin

mean businesses the elaborate have on essentially same margin? a the So little your the your I more diagnostics operating all FX. you -- -- essentially, can bit same

good your segments -- EAS it expansion in in was this what margin quarter life the the So expansion FX is took diagnostic in and from mix about you corporative that and what saw it good other sciences? down about the whereas

Tom Joyce

a Yes. there. couple Well, going on there's of factors

have, FX first the all, and together. of tariffs You

question a maybe Cepheid's above that there. on leverage we And things, was a Cepheid. the you even to And year last And FX tariffs otherwise up two Cepheid combination Beck factors flat mix lower there's of mid bit that, of kind alone a targeted then you'd off that at so numbers those against OMX those Beckman new as greater And than DX and product then had obviously, to, core that. of spend, investment spending as somewhat take get coming DX. operating Beck -- some hair add little of negative to the XX% or Obviously, no margins, single-digits would then probably well we at going growth. bring when up continue our ramp you those component improving Dx,

things. think forward, certainly, as but FX a you I those will really we'll the the look in half a the look we of of those, But tariff the half, little So it's QX, better into and a second see as in combination headwinds OMX second continue bit year, for sure.

Operator

Your next question Ross of comes of from the Evercore. line Muken

Ross Muken

about it I you maybe quite market good are across the of So low broadly? remains on of remaining market on of of the good feel side, comp, of that got elevated you I seem sustaining number of on of end side? business vertical had like kind specifically, then, growth biopharma terms visibility in sort thinking growth how like pretty It single-digit, that underlying. the quarter feels kind tough strong that you've so and parts in terms high the guess, what's, customer end on double-digit think, in kind Pall, Pall And increasingly these like, robust. seen, biotech quite we've kind the of of levels

Tom Joyce

Sure.

core through single-digit we're QX, life science new our quarter, and science at our being put growth and by life this on commercialized -- with a products of beating up And businesses. market is without terrific it strong some In that's, market. we our a off across general, Let's life high products each another quarter. markets start way a in goes organically happen tremendous each science growth investments of in businesses, core. making one effectively, businesses the better end the core good. time, to expectations. innovation very really they're and across fourth our innovative And remain This straight the quarter businesses. in in taking overall to the the IDT And initial more start launched of IDT so here X% one really

sets well So our continued performance solid for execution life markets sciences. end combination I in think of in good really fundamentally up the

been end We of the continue across we're research continue continuous performance have grow but has garnered that applied China, what's as the U.S. use so in in And there the sales well. going closely. solid, market, been bioprocessing And solid, Europe, doing industrially and biopharma And market see that the say academic good stable, the we're our are around we're of science Geographically, a that up areas, And smaller the oriented continuous portions me Europe you've already, I the some end about been interest held seeing is mentioned always to those concerns to strong in good markets single far. life But technologies. watching has sort heard and as tremendous markets solid even work quarter. would it's on is but at moment. marketing.

that watching we're So carefully.

small pharma the In product both terms and biotechs. there, customers of Pall to development visibility and pipelines of going a little large deeper we have good very

continuous think talked those about to business bioreactor prepared I the continue growth this across like continuing bodes that my across innovative biotech growth bioprocessing. work stage single-digit for remarks. And our Pall very that's products well. early and iCELLis the We well double-digit really opportunities SET, And I in what high around

markets the good overall, now. So that to placed it's -- end be right

Ross Muken

investment the there and of that see separation? obviously, you the of now trajectory ahead And I we and put about sort a potential of investments improved. on of the bit sort in comp of made being sort the kind maybe are just the Dental, kind thinking, types business of in are what general, there albeit an guess margin how little of you more growth easier but into

Tom Joyce

we the of put Sure. as stabilization some We're driven to very investments market of commercialization. the performance see been to that innovation product in, actually well stabilization market that But that. up our new underlying encouraged, really that performance beyond we the that the underpins around continue we as and by better top line has invest some believe, the

Some clear those are Nobel. things to aligner new products number around mentioned a our investments our really earlier I like of and specific that program scanner of and intraoral

and set to are business investments -- and so success. and broad we saw we struggled this encouraging, believe we continue quarter, traditional the for the be Even And these in pretty at that's are the where sellout around more consumables If to encouraging, really pretty past, look we to strategically past. important in had equipment, made these be based. the up which with I channel inventories the had think adjusted

Now are in channel shape. good inventories really

So the structure structure years. combined talk with those And investments worked cost think this cost we last four business before hard of around three we over to the how to you we improved I rationalize the about so about heard the establish. and footprint me overall that

think we'll particularly half some incremental second rates, in core I to continue growth the operating in improvements see around margins. the and

So a second than low later and for quarter in expectations. year. positioning the better our I straight I And business we're core the growth well a think single-digit solid think, little

Ross Muken

of versus being the top anything an we equity maybe terms net one, the deep, quick the think came I the line, or if delta, the you organic OMX $X.XX looked with type of of about notable and margin tweak? in Matt, if in operating underlying a And dilution terms segments balanced guide, that more and actually is there fairly QX any up. it's know like it I so. from deal, sort don't the guess, or

Matt McGrew

No.

the think in offset that very think beat $X.XX frame segments, of our thought here. of the for $X.XX full about And operational, kind by offering, was from across of -- got we is the I kind I came change equity the better beat. kind most broad $X.XX kind of dilution your of than year, talking pretty that of of being

that beat it, yes, at effectively, going results here kind dilution So, it's to And think as offset of for way have kind Yes, us year, full growth back, if the the second in a kind into EPS X%, by reduction, quarter. is to $X.XX look call we issuance of of X% it quarter. dilution you the behind the we take about it and of the operational I think step equity got we're is $X.XX here the that now. get $X.XX all from we've

Operator

Doug of Cowen. line question comes the of from Next Schenkel

Doug Schenkel

to expect in X% and X.X%, quarter tougher last growth the Maybe just QX of building against comparison. X% second core off a year-over-year Ross's growth core question, of was you

I haven't comp And months coming an formal of and top QX issues transitory extra in QX. strong. second only we're into uniquely strong two get a positive that I off into made day any year. said, guidance you want not only that While or there's around might tough that to weeks another QX would why quarter heard given that's provide there in were three a selling to suggest anything line understand update the QX has the you any change trend

your core basis year I'm seem So original missing if like it at here? by Is guidance growth there more. XX full on a of mathematically, odd least revenue exceed track to little points, X% anything does you're not bit

Matt McGrew

by said, I like remain three would quarter We've we second last underlying couple as think well. said, before, in of I But July. of mean, to there. get months, to encouraged that folks you done kind We'll Talk of think everybody very full and We'll the of don't are good. here. kind we're dispute I of talked about like that. comeback -- No, worked are that's that QX. the mentioned years, of does half being market we and out kind through The year. we like the kind update second you we we've typically

So that in about at. clearly, of update again we going we're kind everybody we and good do July we're feel But here. where to

Doug Schenkel

low topic bit you is to if in I a heard I second quarter. correctly. The moderated was single-digit performance hoping indicated to SCIEX. more I color get believe the levels on growth that

bit that -- expecting but moderation to It be that pick against you geographic you noted recognizing trends it the comp this your this within peers. hear think continued you would up mix, business every how one SCIEX would I tough more the other at to single-digits ahead, way of on within this demand relative are index just to to in expect that's said up pharma growth clinical end product bid under if year, the SCIEX a I'm and grew then last high to shaped in the up. year. wondering color good the least over were business, bio balance get if you quarter looking And helpful So quarter. be in market

Tom Joyce

sort as core as quarter, by declines this in pretty driven quarter meaningful have up skewed tough fact, first was, 'XX. the We in It towards And growth. of of most know, I largely single-digits, the you the in is was that high single-digit of We mentioned, straight our I market, which think in clinical you've fourth America. North meaningfully coming a quarter, were of we're facts. high point, a at overall. did comp off got first year ago. And

our So of comp particular those that to the direct we kind can to end markets. -- do

farmer other pretty testing end of good. market pretty cannabis testing we sort kind around the really market. look That's academic over solid. are There's grow markets a nascent good. that If solid a pretty and global we pretty The to geographically, markets basis. food The oriented time, market a that good. of are applied on is where The market markets generally expect

we good end aside think comp around about clinical, from relative I that challenging sit markets. we those So where pretty feel to

business We single-digits. footprint an in And separations have good margin as which part was be to SCIEX, both been and high up always mid broader Phenomenex of single-digits generally to tracking That service expansion well, business, continues with at important a consumables. low growth has our today single-digits.

And business So think about some we that that I comp. feel improvement good is we'll positioned time. how see over despite tough

Matt McGrew

of the for like said, outlook expecting from balance kind mid quarter kind year Yes, the here Doug, just we're Tom and an of we second perspective. of and single-digit are here the

Operator

line the Bank. from Leonard comes question of Dan next Deutsche Your of

Dan Leonard

a the with question tools stick will on I business. Hello,

strengths? your on for tools. the first driving here you of and platform? you're there's that seeing Can me, in parts any you flag other of that I'm if So therapies the what cell are some specifically play wondering off, cytometry mentioned strength applications strengths centrifugation and And and Beckman flow

Tom Joyce

Sure, Dan.

an In that have with terms is I is with Xitogen years our areas combination breakthrough of line. lymphomas. more helped flow volumes, innovations market. think been any associated market technologies higher from application architecture oriented end led business And broadly drive towards the different to The the the Centrifugation quarters. volumes. but ago for of been now more of driver few perspective. top with purely cytometry, growth key that to the a of And that leukemia LS just novel embedded our table wouldn't play it of to Beck number product defined in above set attribute a number particular those certainly technologies in of We historical more applications. pretty really have It's for the that's business acquisition strong of technologies centrifugation end kinds of consistently. much was real combination cytometry I CytoFLEX the And, our a segments is and an of a flow strength around generally a

done team's to around positioning a organization of a that products able with in think nice innovation at Beck I market. growth sources done the job in They've being their are terms think centrifugation. LS. terms the across I of nice broadly commercial take end more more to And of those market fragmented job underlying effectively those

Dan Leonard

and business in QX back growth the us the in safe to And to just flu And beyond? offer a is growth it you excluding that double-digit quarter, Cepheid rate that gets the quick follow assume up. Can comp?

Tom Joyce

Yes.

of you was flu if think HBDC kind it excluding high markets Cepheid, the double-digits. stuff, growth in up about So

Operator

the Erin comes question of Credit Your from line Suisse. next of Wright

Erin Wright

Dental us driving et should the do both here? on co So if you're the world could you when your rest can trends update across And business, growth? give that we timeline side, at hear stabilization outlook about you spin, think continuing more breakdown for we're of of North the inflection you an you remain an more point the and And Have Thanks. just cetera? America seen the what's on quarter-to-date? seeing

Tom Joyce

point. I call would know I that don't Erin, this an inflection

channel at point a we're I was seeing a of now now sell-out period, have past, really be to in relationships that stable think, between some And that alignment the of evolved distributors, of when in -- a we maybe a disruption really forces, that rectified, much more between couple manufacturers where over terms market. end things And a year versus among stabilization. both and we of how it to of adjustments channel, bill level relative least it products. we traditional sell-in terms over progressing through terms even needed more in measure our seen we've that some we specialized are three that by and those caused in category of at the the consumables inventories, equipment trending two, last some inventory series some in the things of sales think see the look channel over at look the and all the exclusive I to to stabilization quarters some disruption

the today a than far stable a overall trend could market year And it say the two so, in general, would I in ago. more was or called be certainly

patient area And treatment imaging through treatment important In of imaging dentistry, move are and novel terms would Nobel areas, novel implant those broadly say of to the be what leads where dentistry happening that imaging happening end broader imaging that's trend, basis. market, that's our in digital our to business of in And America, trends areas, that continued those satisfaction. is treatment really procedures based the think planning North systems, just up planning, of in and where continues Kerr in an would not term, leader greater software a to the with and described global really technologies. systems specialty innovations digital in with where technologies leader towards linkage broad but be on levels the I to importance leads execution implant -- around the a in real KaVo I business and as a matters, particularly

finally, equity laid it IPO that would -- timeline a China balance importance certainly we is that of we're XX.X% into Dental market. timeline double the one, we've your the which think probably noteworthy practice across being of is around growth put a the the this digits. of around intention on as a of that’s out, But And the in about that to The a that lot would our thing focused And that demands spin, spin the that of of dentistry growth of and the talked then in on remain late emerging retain was I to markets other of being the year. middle launch putting is class, emerging affect is good markets. greater going class our of business. time. number And to in an largely for middle be period we that high the question we've see an platform business dentistry. where

And those so change there's been plans. to no

Erin Wright

is risk think about related U.S., scrutiny, it comes speak to your to there bigger the a more then instance. What concepts of there more these drug being perspective alone, that factors from are reimbursement meaningfully volatility of When Thanks. How seeing -- of some this to reimbursement And lot market, concepts your concerned could a implemented. of picture there pressures, recently actual the in across that customer you pricing impact anything just and on been anything you actually the kind do of some or is just about for business? PAMA, there? you're here your reimbursement, likelihood a opportunities, the And broader primarily business question, of in regulatory has of kind regardless base? are

Tom Joyce

any around about, dynamics mentioned. you no. in But of having be answer Care incrementally your price Yes, we not material the just bandied whatsoever, on impacts about that immaterial are answer standard procedure then seen Affordable would to lots those cut about Act, question occasional things again, our moment or reimbursement pressures are PAMA, The around are impact. operating are and concerned right markets. of a the there healthcare being the something to we’ve and at the us impact To simple that. today diagnostic

north for the of the patients I about in well central pathology, in back decisions step ill do for care, of to in that anatomical and acute acutely think, yet diagnostic about X% Erin, hospitals XX% laboratory, business in diagnostics molecular today. our the broadly diagnostics, in defined. made think from represents around what healthcare Diagnostics capabilities it infectious ultimately of informs of we moment, disease. you today emergency healthcare room, are in probably a you in providing costs And

be factors of you Today for vital the potential those overall in quarter. while mind, recent market, the relatively in to meaningful us but of been change aware keep And a we attend small are portion of role cost important mentioned in to the So any that any any impacts. play structure. overall there in hasn't the very and are

Operator

Brandon of question of line comes next Jefferies. Couillard from Your

Brandon Couillard

on the follow specifically consumables Dental Tom and first the of the in curious a versus out up Any just quarter you chance period? performance the in tease the how traditional then, portfolio the business. the could lines did specialty business U.S.

Tom Joyce

low of solid, I pretty second growth quarter as single-digit think the I straight mentioned, across platform.

mid couple we on on see all really good business was single-digits, So about we've the of but still years. but And a with a what of comp, line feel and pretty performance up was good stack seen single-digits. we low in orthodontics The Nobel up tougher single-digits across mid that. QX those businesses. last generally X-year basis,

product around through new investments around a innovation. in both we're significant clear scanners support the difference cases, business orthodontics in that liners making make will time. over really Obviously, our in I think intraoral consumables, specialty digital then of and these

that as going the And level, time. surface difference We introduced make line technologies Damon market Nobel, at have over new are products Damon technologies have new been are exciting into a these new to well. then that

out those traditional that and think really consumables tracking remain new And reasonably in are I the by business, American as encouraged we coming market. we're today both And so, stable product around seeing reasonably a of businesses the when sell-out the sell-out, mid solid. are with We're innovations well, at growth but equipment trends growth them. looks single-digit single-digit are look pretty good. low imaging. good, The imaging North

to channel are inventories make sure line. sell-in the to we're continuing manage So in

of that think, today. where we overall, good have future. platform the don't fits in we disruption the I And Dental So about feel kind pretty

Brandon Couillard

And you And guess the And about the five what follow-up pricing? in business? to do weakness where up continues talk sustainability solid, for somewhat improve of be EAS what's and so from? X.X Dental maybe pretty that think you of pricing been, a of Can I segment pricing Dental might on secondly, the quarters that's coming Matt. period. about

Matt McGrew

sure intentional to that say in going that four we've was not for is range I Dental. that -- driving last the or that anything five in that's I'm Yes, general kind quarters. got of

to seems operate of they here runway today. that kind So the of where be

or sure not kind an of for there's Dental. inflection change necessarily that's I'm So being planned

As very do job in goes, pricing. yes, far as a nice EAS they

prices businesses through of been of to I the have passing some think around a of both And do we talked some that than other -- of bit they're the longer and kind of little they get. businesses. able that things it's our those about some

that a either. I'm not perspective trend sure from So there's change there anything will

or seen a price in five was we've price there in quarter that range lot new four that I not the here for perspective. whole the from I'm think quarters. sure last

Operator

one We have time for more question.

come will line final Our of question UBS. Brennan of the Daniel from

Daniel Brennan

wanted starting first to ask I GE. on

customer If combined you're some feedback providing if of share you should I at could the -- receiving, customers possibly the the provider? some early some gains Danaher that some that share learn broader and GE to look mean maybe solutions of possible offerings, be

Tom Joyce

actually and broader we spent the with time. only number I overall share workflow, market see that expensive we we time broadly don't that their think that but in quite with of those end bioprocessing bring of as where in ensure business. And I towards to I the Danaher to end today, across the real represent portfolio, customers. Pall of job set towards And not share meet GE is as They tools was China they of Our more use does of I expands the where the at in broader key as bioproduction continuous team the see tremendous week opportunities was opportunity ago, something capacity market then exciting. their processes, the that the they'll being situations not they a portfolio broad view two across earlier our evolve single And their a to think does solutions met capabilities. really bring last and or we innovative customers actually of really the with mentioned obviously -- that potentially broader market. of customers has perspective more as bring actually, inclusive a technologies needs over GE collaboratively customers them end work the weeks associated but for I just that and one today of and Pall, market. with China of sort my a have the needs combination solutions enthusiasm. customers. in in a are can comment, And we also We to

Daniel Brennan

has of mark secular is. you. different Maybe And there, grinding the final for maybe likely. just growth but with four some ongoing China if all one just that's on different runway where dependent the tariff tremendous your Obviously, businesses noise kind their with initiatives follow will? do sustainable out -- kind how upon still amongst secular with the you characterize China. biggest been could see that has up just lower, a China always the in Thank the build like of Where economy growth and you of is you question

Tom Joyce

are the those that investments would important that the a leadership about needs think we China, in I in when ago, we life around markets for mentioned, dynamics, the advanced really, one feel made has environment, that I dentistry, around all drivers in I diagnostics, think say, secular the four being there class us and with along those because served I choose well and position mentioned. to hard almost just middle are of minutes evolving It's past. of markets Daniel. sciences, our in each Thanks, and of the just an And in in Sure. couple in

great in those and enhance the for positions for innovation innovative China new who novel many continued are end Those and designed to investments in in. China, combined market, products, We facing made markets drive are feet customers. of are with continue in solutions that with to are street the on leadership and continually Chinese for which some just of market which be looking end associates to

that sure, I I'm a we diagnostics sciences, future. from will past, the and secular not and in think in Dental benefited benefit markets, the differentiate life I'd benefit they end represent the great So because important have between drivers deal we all the from the necessarily environmental

Operator

will closing to I Thank Gugino the remarks. additional you. Matt call or for any now turn

Matt Gugino

joining We're day everyone, thanks, for questions. all And Laurie. for Thanks, us. around

Operator

Thank First Earnings Danaher you Quarter for Results Corporation's Call. XXXX participating Conference in

disconnect. now You may

Danaher (DHR) 18 Apr 192019 Q1 Earnings call transcript